Newsletter May 2017 No. 179
Top News
The 29th JPMA Policy Seminar" held
On March 1, 2017, the 29th JPMA Policy Seminar was held at the Tokyo Conference Center Shinagawa under the theme of "Drug Discovery Innovation and the Future of the Pharmaceutical Industry. The pharmaceutical industry, which has achieved dramatic growth based on sustained innovation, is now at a major turning point. Innovative new drugs, which have been welcomed with open arms in the past, are now causing controversy leading to a review of the NHI drug price system. The era of simply creating a good product and having it be accepted is over, and the pharmaceutical industry faces the challenge of bringing innovative new drugs to market at low cost and in a short time. The question is what is the substance of innovation? In this policy seminar, the bold use of external resources in the R&D field and organic collaboration between industry, academia, and government, including the use of clinical information, were discussed to promote innovation even more efficiently, and many participants listened attentively.
Topics
- The 3rd Meeting of Code Compliance Managers/Practicing Managers
- Report on the medU-net × JPMA × AMED Joint Forum - Industry-Academia Partnership for New Drug Discovery
- The 8th Workshop on Environmental Technology
- The 19th Symposium on Pharmaceutical Quality Forum
- 2017 Life Science Intellectual Property Forum
- Results of the 2016 "Recommendation, New Drug Campaign" Questionnaire
- JPMA Consumer Consultation Review Committee 2017 "JPMA Consumer Consultation Review Committee Forum" held
- The 4th Japan-Thailand Joint Symposium" held
Connecting with Citizens and Patients
The 5th Advisory Board for Patient Groups" held at Takeda's Shonan Research Center.
Policy Research Institute
From JPMA
Promoting Open Innovation through Diverse Collaborations that Transcend Existing Boundaries